Biogen: Depression trials
The registry lists 11 Depression studies with Biogen as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 1Phase 2 2Phase 3 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderCompletedNCT04476030Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)CompletedNCT04442503Phase 3Results posted
- A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)CompletedNCT04442490Phase 3Results posted
- A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderTerminatedNCT04007367Phase 3Results posted
- A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)CompletedNCT03864614Phase 3Results posted
- A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaTerminatedNCT03771664Phase 3Results posted
- A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeCompletedNCT03692910Phase 2Results posted
- A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderCompletedNCT03672175Phase 3Results posted
- A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive DisorderCompletedNCT03000530Phase 2Results posted
- A Study to Evaluate SAGE-217 in Participants With Severe Postpartum DepressionCompletedNCT02978326Phase 3Results posted
- Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)CompletedNCT05655507Phase 1